Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
1863
99.7K+
LTM Revenue $48.4B
LTM EBITDA $10.5B
$55.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bayer has a last 12-month revenue of $48.4B and a last 12-month EBITDA of $10.5B.
In the most recent fiscal year, Bayer achieved revenue of $49.7B and an EBITDA of $10.9B.
Bayer expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Bayer valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $52.9B | $49.7B | $48.3B | $48.4B | XXX |
Gross Profit | $28.4B | $32.2B | $29.1B | XXX | XXX |
Gross Margin | 54% | 65% | 60% | XXX | XXX |
EBITDA | $13.6B | $10.9B | $10.5B | $10.5B | XXX |
EBITDA Margin | 26% | 22% | 22% | 22% | XXX |
Net Profit | $1.0B | $4.3B | -$3.1B | XXX | XXX |
Net Margin | 2% | 9% | -6% | XXX | XXX |
Net Debt | $35.2B | $36.4B | $37.2B | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 10, 2025, Bayer's stock price is EUR 21 (or $22).
Bayer has current market cap of EUR 20.6B (or $21.4B), and EV of EUR 52.9B (or $55.1B).
See Bayer trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$55.1B | $21.4B | XXX | XXX | XXX | XXX | $5.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 10, 2025, Bayer has market cap of $21.4B and EV of $55.1B.
Bayer's trades at 1.1x LTM EV/Revenue multiple, and 5.3x LTM EBITDA.
Analysts estimate Bayer's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Bayer and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $55.1B | XXX | XXX | XXX |
EV/Revenue | 1.1x | XXX | XXX | XXX |
EV/EBITDA | 5.2x | XXX | XXX | XXX |
P/E | 4.2x | XXX | XXX | XXX |
P/E/Growth | -5.3x | XXX | XXX | XXX |
EV/FCF | 23.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBayer's NTM/LTM revenue growth is 0%
Bayer's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Bayer's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Bayer's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Bayer and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | -3% | XXX | XXX | XXX | XXX |
EBITDA Margin | 22% | XXX | XXX | XXX | XXX |
EBITDA Growth | -3% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 22% | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | 26% | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
Opex to Revenue | 42% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bayer acquired XXX companies to date.
Last acquisition by Bayer was XXXXXXXX, XXXXX XXXXX XXXXXX . Bayer acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Bayer founded? | Bayer was founded in 1863. |
Where is Bayer headquartered? | Bayer is headquartered in Germany. |
How many employees does Bayer have? | As of today, Bayer has 99.7K+ employees. |
Is Bayer publicy listed? | Yes, Bayer is a public company listed on ETR. |
What is the stock symbol of Bayer? | Bayer trades under BAYN ticker. |
When did Bayer go public? | Bayer went public in 1953. |
Who are competitors of Bayer? | Similar companies to Bayer include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
What is the current market cap of Bayer? | Bayer's current market cap is $21.4B |
What is the current revenue of Bayer? | Bayer's last 12-month revenue is $48.4B. |
What is the current EBITDA of Bayer? | Bayer's last 12-month EBITDA is $10.5B. |
What is the current EV/Revenue multiple of Bayer? | Current revenue multiple of Bayer is 1.1x. |
What is the current EV/EBITDA multiple of Bayer? | Current EBITDA multiple of Bayer is 5.3x. |
What is the current revenue growth of Bayer? | Bayer revenue growth between 2023 and 2024 was -3%. |
Is Bayer profitable? | Yes, Bayer is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.